Sean P Heffron1, Maija K Ruuth2, Yuhe Xia3, Gustavo Hernandez3, Lauri Äikäs2, Crystalann Rodriguez3, Katariina Öörni4, Jeffrey S Berger5. 1. NYU Grossman School of Medicine, Leon H. Charney Division of Cardiology, United States; NYU Grossman School of Medicine, NYU Center for the Prevention of Cardiovascular Disease, United States. 2. Wihuri Research Institute, Finland; Research Programs Unit, Faculty of Medicine, University of Helsinki, Finland. 3. NYU Grossman School of Medicine, Leon H. Charney Division of Cardiology, United States. 4. Wihuri Research Institute, Finland; Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki Helsinki, Finland. Electronic address: kati.oorni@wri.fi. 5. NYU Grossman School of Medicine, Leon H. Charney Division of Cardiology, United States; NYU Grossman School of Medicine, NYU Center for the Prevention of Cardiovascular Disease, United States; NYU Grossman School of Medicine, Department of Surgery, New York, NY, United States. Electronic address: jeffrey.berger@nyumc.org.
Abstract
BACKGROUND AND AIMS: Peripheral artery disease (PAD) is a systemic manifestation of atherosclerosis that is associated with a high risk of major adverse cardiovascular events (MACE). LDL aggregation contributes to atherosclerotic plaque progression and may contribute to plaque instability. We aimed to determine if LDL aggregation is associated with MACE in patients with PAD undergoing lower extremity revascularization (LER). METHODS: Two hundred thirty-nine patients with PAD undergoing LER had blood collected at baseline and were followed prospectively for MACE (myocardial infarction, stroke, cardiovascular death) for one year. Nineteen age, sex and LDL-C-matched control subjects without cardiovascular disease also had blood drawn. Subject LDL was exposed to sphingomyelinase and LDL aggregate size measured via dynamic light scattering. RESULTS: Mean age was 72.3 ± 10.9 years, 32.6% were female, and LDL-cholesterol was 68 ± 25 mg/dL. LDL aggregation was inversely associated with triglycerides, but not associated with demographics, LDL-cholesterol or other risk factors. Maximal LDL aggregation occurred significantly earlier in subjects with PAD than in control subjects. 15.9% of subjects experienced MACE over one year. The 1st tertile (shortest time to maximal aggregation) exhibited significantly higher MACE (25% vs. 12.5% in tertile 2 and 10.1% in tertile 3, p = 0.012). After multivariable adjustment for demographics and CVD risk factors, the hazard ratio for MACE in the 1st tertile was 4.57 (95% CI 1.60-13.01; p = 0.004) compared to tertile 3. Inclusion of LDL aggregation in the Framingham Heart Study risk calculator for recurrent coronary heart disease events improved the c-index from 0.57 to 0.63 (p = 0.01). CONCLUSIONS: We show that in the setting of very well controlled LDL-cholesterol, patients with PAD with the most rapid LDL aggregation had a significantly elevated MACE risk following LER even after multivariable adjustment. This measure further improved the classification specificity of an established risk prediction tool. Our findings support broader investigation of this assay for risk stratification in patients with atherosclerotic CVD.
BACKGROUND AND AIMS: Peripheral artery disease (PAD) is a systemic manifestation of atherosclerosis that is associated with a high risk of major adverse cardiovascular events (MACE). LDL aggregation contributes to atherosclerotic plaque progression and may contribute to plaque instability. We aimed to determine if LDL aggregation is associated with MACE in patients with PAD undergoing lower extremity revascularization (LER). METHODS: Two hundred thirty-nine patients with PAD undergoing LER had blood collected at baseline and were followed prospectively for MACE (myocardial infarction, stroke, cardiovascular death) for one year. Nineteen age, sex and LDL-C-matched control subjects without cardiovascular disease also had blood drawn. Subject LDL was exposed to sphingomyelinase and LDL aggregate size measured via dynamic light scattering. RESULTS: Mean age was 72.3 ± 10.9 years, 32.6% were female, and LDL-cholesterol was 68 ± 25 mg/dL. LDL aggregation was inversely associated with triglycerides, but not associated with demographics, LDL-cholesterol or other risk factors. Maximal LDL aggregation occurred significantly earlier in subjects with PAD than in control subjects. 15.9% of subjects experienced MACE over one year. The 1st tertile (shortest time to maximal aggregation) exhibited significantly higher MACE (25% vs. 12.5% in tertile 2 and 10.1% in tertile 3, p = 0.012). After multivariable adjustment for demographics and CVD risk factors, the hazard ratio for MACE in the 1st tertile was 4.57 (95% CI 1.60-13.01; p = 0.004) compared to tertile 3. Inclusion of LDL aggregation in the Framingham Heart Study risk calculator for recurrent coronary heart disease events improved the c-index from 0.57 to 0.63 (p = 0.01). CONCLUSIONS: We show that in the setting of very well controlled LDL-cholesterol, patients with PAD with the most rapid LDL aggregation had a significantly elevated MACE risk following LER even after multivariable adjustment. This measure further improved the classification specificity of an established risk prediction tool. Our findings support broader investigation of this assay for risk stratification in patients with atherosclerotic CVD.
Authors: Marc P Bonaca; Patrice Nault; Robert P Giugliano; Anthony C Keech; Armando Lira Pineda; Estella Kanevsky; Julia Kuder; Sabina A Murphy; J Wouter Jukema; Basil S Lewis; Lale Tokgozoglu; Ransi Somaratne; Peter S Sever; Terje R Pedersen; Marc S Sabatine Journal: Circulation Date: 2017-11-13 Impact factor: 29.690
Authors: Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano; Marie-Therese Cooney Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: Sean P Heffron; Caron B Rockman; Mark A Adelman; Eugenia Gianos; Yu Guo; Jin Feng Xu; Jeffrey S Berger Journal: Arterioscler Thromb Vasc Biol Date: 2017-05-18 Impact factor: 8.311
Authors: Maija Ruuth; Laura G M Janssen; Lauri Äikäs; Feven Tigistu-Sahle; Kimberly J Nahon; Olli Ritvos; Hanna Ruhanen; Reijo Käkelä; Mariëtte R Boon; Katariina Öörni; Patrick C N Rensen Journal: J Clin Lipidol Date: 2019-09-30 Impact factor: 4.766
Authors: C Hallberg; M Hådén; M Bergström; G Hanson; K Pettersson; C Westerlund; G Bondjers; A M Ostlund-Lindqvist; G Camejo Journal: J Lipid Res Date: 1994-01 Impact factor: 5.922
Authors: Birgitta Sigvant; Katarina Wiberg-Hedman; David Bergqvist; Olov Rolandsson; Bob Andersson; Elisabeth Persson; Eric Wahlberg Journal: J Vasc Surg Date: 2007-06 Impact factor: 4.268
Authors: Jan Borén; M John Chapman; Ronald M Krauss; Chris J Packard; Jacob F Bentzon; Christoph J Binder; Mat J Daemen; Linda L Demer; Robert A Hegele; Stephen J Nicholls; Børge G Nordestgaard; Gerald F Watts; Eric Bruckert; Sergio Fazio; Brian A Ference; Ian Graham; Jay D Horton; Ulf Landmesser; Ulrich Laufs; Luis Masana; Gerard Pasterkamp; Frederick J Raal; Kausik K Ray; Heribert Schunkert; Marja-Riitta Taskinen; Bart van de Sluis; Olov Wiklund; Lale Tokgozoglu; Alberico L Catapano; Henry N Ginsberg Journal: Eur Heart J Date: 2020-06-21 Impact factor: 29.983
Authors: Maija Ruuth; Su Duy Nguyen; Terhi Vihervaara; Mika Hilvo; Teemu D Laajala; Pradeep Kumar Kondadi; Anton Gisterå; Hanna Lähteenmäki; Tiia Kittilä; Jenni Huusko; Matti Uusitupa; Ursula Schwab; Markku J Savolainen; Juha Sinisalo; Marja-Liisa Lokki; Markku S Nieminen; Antti Jula; Markus Perola; Seppo Ylä-Herttula; Lawrence Rudel; Anssi Öörni; Marc Baumann; Amos Baruch; Reijo Laaksonen; Daniel F J Ketelhuth; Tero Aittokallio; Matti Jauhiainen; Reijo Käkelä; Jan Borén; Kevin Jon Williams; Petri T Kovanen; Katariina Öörni Journal: Eur Heart J Date: 2018-07-14 Impact factor: 29.983